Skip to main content
Fig. 4 | The Journal of Headache and Pain

Fig. 4

From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data

Fig. 4

Median headache days and intensity and patients distribution according to MIDAS and HIT-6 scores during the 3 months before onabotulinumtoxin A initiation and during the final 3 months of follow-up. Results are stratified by response status. The asterisk (*) identifies significant changes compared with pre-treatment. NR indicates non-responders; AR, anytime responders; SR, sustained responders

Back to article page